140 related articles for article (PubMed ID: 33092743)
1. Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Amat-Santos IJ; Santos-Martinez S; López-Otero D; Delgado-Arana JR; San Román JA
J Am Coll Cardiol; 2020 Oct; 76(17):2042. PubMed ID: 33092743
[No Abstract] [Full Text] [Related]
2. ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Wang Y; Tse G; Li G; Lip GYH; Liu T
J Am Coll Cardiol; 2020 Oct; 76(17):2041. PubMed ID: 33092742
[No Abstract] [Full Text] [Related]
3. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
4. Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Kansagara D; Mackey K; Vela K
Ann Intern Med; 2020 Aug; 173(3):W66. PubMed ID: 32584593
[No Abstract] [Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.
Verdecchia P; Angeli F; Reboldi G
J Hypertens; 2020 Jun; 38(6):1190-1191. PubMed ID: 32371811
[No Abstract] [Full Text] [Related]
6. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Diaz JH
J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
[TBL] [Abstract][Full Text] [Related]
7. Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic".
Ferrario CM
Diabetes Metab Syndr; 2020; 14(5):1401-1402. PubMed ID: 32755842
[No Abstract] [Full Text] [Related]
8. Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Sep; 173(5):W87. PubMed ID: 32701362
[No Abstract] [Full Text] [Related]
9. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Gersh FL
Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
[No Abstract] [Full Text] [Related]
10. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment.
De Cauwer H
Intern Emerg Med; 2020 Nov; 15(8):1581-1582. PubMed ID: 32564289
[No Abstract] [Full Text] [Related]
11. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Guo J; Huang Z; Lin L; Lv J
J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
[No Abstract] [Full Text] [Related]
12. COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
Kussmaul WG
Ann Intern Med; 2020 Aug; 173(3):237-238. PubMed ID: 32422077
[TBL] [Abstract][Full Text] [Related]
13. Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
Aamodt AH; Bjørk MH; Tronvik EA; Buanes EA; Stovner LJ; Atar D
Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549022
[No Abstract] [Full Text] [Related]
14. Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
Vavougios GD
Crit Care; 2020 May; 24(1):242. PubMed ID: 32430049
[No Abstract] [Full Text] [Related]
15. Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic.
Speth RC
J Travel Med; 2020 May; 27(3):. PubMed ID: 32268374
[No Abstract] [Full Text] [Related]
16. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
17. Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Oct; 173(7):130-131. PubMed ID: 32845705
[No Abstract] [Full Text] [Related]
18. Controversy regarding ACE inhibitors / ARBs in COVID-19.
Soria Arcos F; Romero Puche A; Vicente Vera T
Rev Esp Cardiol (Engl Ed); 2020 Jun; 73(6):516. PubMed ID: 32371022
[No Abstract] [Full Text] [Related]
19. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
20. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.
Sunden-Cullberg J
Hypertension; 2020 Jun; 75(6):e15-e16. PubMed ID: 32275190
[No Abstract] [Full Text] [Related]
[Next] [New Search]